Small-Cap ETFs to Rally on Upbeat U.S. Q2 GDP Growth Data?
US Economic Growth: The US economy grew at an annualized rate of 2.8% in Q2 2024, surpassing expectations, while small-cap stocks have outperformed larger indices amid a shift in investor focus and potential Fed rate cuts.
Earnings Outlook: S&P 500 earnings are projected to rise by 9.6% in Q2, while small-cap earnings are expected to decline by 7.9%, indicating a slow improvement in the small-cap segment despite ongoing economic challenges.
Trade with 70% Backtested Accuracy
Analyst Views on SBIO
No data
About the author
Eight Stock Selections to Capitalize on a Robust Sector of the Market
Healthcare Sector Valuation: The U.S. healthcare sector is currently attractively priced, with a forward price/earnings (P/E) ratio of 18.2, appealing to investors wary of the overall market's high valuations.
Comparison with S&P 500: The healthcare sector's forward P/E is a 12% premium over its 10-year average, while the broader S&P 500 has a forward P/E of 22.4, which is a 19% premium to its historical average.
Biotech ETFs Make a Comeback in 2025: Reasons Behind the Recovery
Biotech ETF Performance: The iShares Biotechnology ETF (IBB) has outperformed the SPDR S&P 500 ETF Trust (SPY) with a 30.2% increase over the past six months, while the broader MSCI USA Pharmaceuticals, Biotechnology and Life Sciences Index has shown muted returns of 3.74% in 2024.
Market Dynamics and Growth Potential: Despite recent gains, biotech stocks are trading below the broader market, with favorable forward P/E ratios and projected EPS growth, indicating potential for further investment, especially in a declining interest rate environment.
Small-Cap ETFs to Rally on Upbeat U.S. Q2 GDP Growth Data?
US Economic Growth: The US economy grew at an annualized rate of 2.8% in Q2 2024, surpassing expectations, while small-cap stocks have outperformed larger indices amid a shift in investor focus and potential Fed rate cuts.
Earnings Outlook: S&P 500 earnings are projected to rise by 9.6% in Q2, while small-cap earnings are expected to decline by 7.9%, indicating a slow improvement in the small-cap segment despite ongoing economic challenges.
SBIO, XBI, or BBP: Which is the Best Biotech ETF, According to Analysts?
Biotechnology Sector Overview:
- Biotech sector known for high risks but appealing long-term prospects.
- Companies focus on R&D for medical needs and tech advancements.
Investing in BioTech ETFs:
- Suitable for less savvy investors to diversify risks.
- Considered a defensive play against economic challenges.
Comparison of BioTech ETFs:
- Used TipRanks' tool to compare SBIO, XBI, and BBP.
- Ratings and targets based on consolidated stock data in each fund.
Specific BioTech ETF Details:
- SBIO: Strong Buy consensus, $65.62 price target.
- XBI: Strong Buy consensus, $158.37 price target.
- BBP: Strong Buy consensus, $99.71 price target.
Future Outlook:
- Analysts favor SBIO for significant upside potential.
- SBIO focuses on clinical-stage biotech companies with growth potential.
This biotech ETF sees ‘breakout’ while U.S. small-cap technology stocks lag
Eight Stock Selections to Capitalize on a Robust Sector of the Market
Healthcare Sector Valuation: The U.S. healthcare sector is currently attractively priced, with a forward price/earnings (P/E) ratio of 18.2, appealing to investors wary of the overall market's high valuations.
Comparison with S&P 500: The healthcare sector's forward P/E is a 12% premium over its 10-year average, while the broader S&P 500 has a forward P/E of 22.4, which is a 19% premium to its historical average.
Biotech ETFs Make a Comeback in 2025: Reasons Behind the Recovery
Biotech ETF Performance: The iShares Biotechnology ETF (IBB) has outperformed the SPDR S&P 500 ETF Trust (SPY) with a 30.2% increase over the past six months, while the broader MSCI USA Pharmaceuticals, Biotechnology and Life Sciences Index has shown muted returns of 3.74% in 2024.
Market Dynamics and Growth Potential: Despite recent gains, biotech stocks are trading below the broader market, with favorable forward P/E ratios and projected EPS growth, indicating potential for further investment, especially in a declining interest rate environment.
Small-Cap ETFs to Rally on Upbeat U.S. Q2 GDP Growth Data?
US Economic Growth: The US economy grew at an annualized rate of 2.8% in Q2 2024, surpassing expectations, while small-cap stocks have outperformed larger indices amid a shift in investor focus and potential Fed rate cuts.
Earnings Outlook: S&P 500 earnings are projected to rise by 9.6% in Q2, while small-cap earnings are expected to decline by 7.9%, indicating a slow improvement in the small-cap segment despite ongoing economic challenges.
SBIO, XBI, or BBP: Which is the Best Biotech ETF, According to Analysts?
Biotechnology Sector Overview:
- Biotech sector known for high risks but appealing long-term prospects.
- Companies focus on R&D for medical needs and tech advancements.
Investing in BioTech ETFs:
- Suitable for less savvy investors to diversify risks.
- Considered a defensive play against economic challenges.
Comparison of BioTech ETFs:
- Used TipRanks' tool to compare SBIO, XBI, and BBP.
- Ratings and targets based on consolidated stock data in each fund.
Specific BioTech ETF Details:
- SBIO: Strong Buy consensus, $65.62 price target.
- XBI: Strong Buy consensus, $158.37 price target.
- BBP: Strong Buy consensus, $99.71 price target.
Future Outlook:
- Analysts favor SBIO for significant upside potential.
- SBIO focuses on clinical-stage biotech companies with growth potential.
This biotech ETF sees ‘breakout’ while U.S. small-cap technology stocks lag
